Clinical Trials

Pancreatic Neoplasms

NCT04683315 2026-03-05

PANCREAS

84 enrolled

Pancreatic Neoplasms

NCT02021422 2026-02-18

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

13 enrolled

Phase 3 Active not recruiting

Pancreatic Neoplasms

NCT04340141 2026-02-10

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

358 enrolled

Pancreatic Neoplasms

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

35 enrolled

Pancreatic Neoplasms

NCT06958328 2026-02-02

LAP100

Phase 3 Recruiting

356 enrolled

Pancreatic Neoplasms

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT04421820 2026-01-27

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Phase 1/2 Recruiting

220 enrolled

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05026905 2026-01-20

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

66 enrolled

Phase NA Not yet recruiting

Pancreatic Neoplasms

NCT07325214 2026-01-12

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

136 enrolled

Pancreatic Neoplasms

NCT03322995 2026-01-08

PANC

125 enrolled

Pancreatic Neoplasms

NCT03443492 2025-12-30

Pancreas

Phase 2 Completed

130 enrolled

Pancreatic Neoplasms

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled

Phase 3 Active not recruiting

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT06625320 2025-12-12

RASolute 302

501 enrolled

Pancreatic Neoplasms

NCT06941857 2025-12-03

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

20 enrolled

Carcinoma, Pancreatic Neoplasms

NCT05417386 2025-11-18

FOLFIRINOX + NIS793 in Pancreatic Cancer

Phase 1 Terminated

4 enrolled

Phase 1/2 Active not recruiting

Pancreatic Neoplasms

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

120 enrolled

Pancreatic Neoplasms

NCT04141995 2025-08-07

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

Phase 2 Terminated

11 enrolled

Pancreatic Neoplasms

NCT04594772 2025-07-02

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

32 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03750669 2025-05-13

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Phase 3 Completed

324 enrolled

DermatologicGastrointestinal

Pancreatic Neoplasms

NCT06483555 2025-04-16

PANGEA

Phase 1/2 Recruiting

104 enrolled

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT03822936 2025-02-13

PIOPPO

Phase 2 Terminated

30 enrolled

Pancreatic Neoplasms

NCT06538207 2025-02-06

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

46 enrolled

Pancreatic Neoplasms

NCT03699319 2025-01-23

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Phase 1/2 Completed

49 enrolled

Pancreatic Neoplasms

NCT06766019 2025-01-09

Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

47 enrolled

Pancreatic Neoplasms

NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

9 enrolled

Phase 1/2 Active not recruiting

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05121038 2024-12-17

CENDIFOX

50 enrolled

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT05546411 2024-12-17

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Phase 2 Terminated

8 enrolled 11 charts

Pancreatic Neoplasms

NCT05859750 2024-12-16

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

78 enrolled

Pancreatic Neoplasms

NCT03329248 2024-12-12

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

6 enrolled 15 charts

Pancreatic Neoplasms

NCT01905150 2024-12-11

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Phase 2 Completed

34 enrolled 10 charts

Pancreatic Neoplasms

NCT06094140 2024-12-03

NEO-IMPACT

20 enrolled

Phase 2/3 Active not recruiting

Pancreatic Neoplasms

NCT02919787 2024-11-20

Nordic Pancreatic Cancer Trial (NorPACT) - 1

140 enrolled

Pancreatic Neoplasms

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT06532344 2024-11-14

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Phase 1 Active not recruiting

32 enrolled

Pancreatic Neoplasms

NCT04927780 2024-08-28

PREOPANC-3

Phase 3 Recruiting

378 enrolled

Pancreatic Neoplasms

NCT03586869 2024-08-27

QUILT-3.080: NANT Pancreatic Cancer Vaccine

3 enrolled 13 charts

Pancreatic Neoplasms

NCT06538623 2024-08-27

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

40 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT03136406 2024-06-11

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

3 enrolled 9 charts

Pancreatic Neoplasms

NCT03387098 2024-05-22

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

4 enrolled 9 charts

Pancreatic Neoplasms

NCT04672005 2024-05-16

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT04447092 2024-04-19

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

77 enrolled

Pancreatic Neoplasms

NCT06361316 2024-04-11

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Phase NA Recruiting

53 enrolled

Pancreatic Neoplasms

NCT05048524 2024-03-27

Peri-operative SLOG for Localized Pancreatic Cancer

64 enrolled

Phase 1/2 Not yet recruiting

Pancreatic Neoplasms

NCT06259058 2024-03-15

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

96 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06217042 2024-01-22

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Phase 3 Not yet recruiting

524 enrolled

Phase 2 Not yet recruiting

Pancreatic Neoplasms

NCT06210360 2024-01-18

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

134 enrolled